U.S. FDA Granted Priority Review to Dizal’s Sunvozertinib New Drug Application
If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented at the 2024 ASCO Annual Meeting SHANGHAI,...
Weimai bags RMB200m in Series D funding to enhance tech-enabled, continuous healthcare services
The latest funding round will fuel Weimai's efforts to expand its full-cycle healthcare solutions, leveraging AI and digital tools to provide comprehensive care across China HANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Weimai, a leading provider of one-stop digital healthcare solutions in China, has completed a Series D funding round, raising 200 million yuan ($27.3 million). ...
Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference
HONG KONG and SAN FRANCISCO, Jan. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place on January 13, 2025, in San Francisco, California. The company's founder, chairwoman, president, and CEO, Dr. Michelle Xia will share the latest developments and...
NUS researchers boost chemotherapy uptake in breast cancer treatment with localised magnetic fields
A recent study explained the mechanisms by which pulsed electromagnetic field therapy enhances doxorubicin uptake, paving the way for precision-driven cancer therapies with fewer side effects SINGAPORE, Jan. 7, 2025 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness of chemotherapy while...
The Registrational Clinical Data of Glecirasib was Published in Nature Medicine
BEIJING, SHANGHAI and BOSTON, Jan. 7, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset...
WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager
SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced an agreement with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell engagers for autoimmune and inflammatory diseases. Under the terms of the agreement, Candid...
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releasesNext media release LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in Australia, Switzerland and the United Kingdom. This milestone further...
DXC Technology’s AI Impact Helps Customers Across Industries Innovate with AI
AI Impact leverages DXC's combined consulting, engineering, and secure enterprise services ASHBURN, Va., Jan. 6, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced AI Impact, an approach designed to help solve customers' most pressing challenges. By combining DXC consulting, engineering and secure enterprise services, DXC will help clients across industries securely innovate and...
VIV™ Ring: The World’s 1st Smart Ring with Generative Sleep Aid Sound at CES 2025
The Intuitive Smart Ring Challenging Oura and Galaxy Ring Generative Sleep Aid Sound Enhancing Beyond Biometrics Measurement LAS VEGAS, Jan. 6, 2025 /PRNewswire/ -- VIV Health is thrilled to announce the upcoming launch of the VIV™ Ring, the world's first smart ring equipped with Generative Sleep aid sound, at CES 2025, starting January 7. This innovative device goes...
Momcozy 2024 Year in Review: Capturing the Power of Comfort and Growth
NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The global one-stop mother and baby brand Momcozy has unveiled its annual review video alongside a user testimonial video. In its annual review, Momcozy highlighted key achievements of 2024, showcasing its commitment to empowering mothers through innovative campaigns and partnerships. The year was marked by significant collaborations and community-focused initiatives that reinforced the...
